Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Mendelson

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|March 1, 2016
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsJeffrey R Infante, David S Mendelson, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Radiology|April 17, 2019
A Roadmap for Foundational Research on Artificial Intelligence in Medical Imaging: From the 2018 NIH/RSNA/ACR/The Academy WorkshopCurtis P Langlotz, Bibb Allen, Bradley J Erickson, et al.
Academic Radiology|December 3, 2015
Patient-directed Internet-based Medical Image Exchange: Experience from an Initial Multicenter ImplementationGiampaolo Greco, Anand S Patel, Sara C Lewis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancerRoy S Herbst, S Gail Eckhardt, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancerLee S Rosen, Herbert I Hurwitz, Michael K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.
Clinical Genitourinary Cancer|December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaDavid S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
Clinical Imaging|March 8, 2011
CT- and computer-based features of small hamartomasYao Huang, Dong ming Xu, Artit Jirapatnakul, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|March 1, 2016
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsJeffrey R Infante, David S Mendelson, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Radiology|April 17, 2019
A Roadmap for Foundational Research on Artificial Intelligence in Medical Imaging: From the 2018 NIH/RSNA/ACR/The Academy WorkshopCurtis P Langlotz, Bibb Allen, Bradley J Erickson, et al.
Academic Radiology|December 3, 2015
Patient-directed Internet-based Medical Image Exchange: Experience from an Initial Multicenter ImplementationGiampaolo Greco, Anand S Patel, Sara C Lewis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancerRoy S Herbst, S Gail Eckhardt, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancerLee S Rosen, Herbert I Hurwitz, Michael K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.
Clinical Genitourinary Cancer|December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaDavid S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
Clinical Imaging|March 8, 2011
CT- and computer-based features of small hamartomasYao Huang, Dong ming Xu, Artit Jirapatnakul, et al.
Pageof 5